Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18956343 | 0.92 | ALDH1A1 (0.70) | PKMSMN1; SMN2L3MBTL1ALDH1A1LMNA | |
| SCHEMBL4687548 | 0.85 | FFAR2 (0.74) | SMN1; SMN2L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL24359465 | 0.84 | ALDH1A1 (0.58) | PKMSMN1; SMN2L3MBTL1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL29855979 | 0.84 | FFAR2 (0.72) | SMN1; SMN2L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL27524988 | 0.83 | POLB (0.55) | PKML3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL9975588 | 0.83 | ALDH1A1 (0.59) | PKMSMN1; SMN2L3MBTL1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11320626 | 0.81 | SMN1; SMN2 (0.65) | SMN1; SMN2L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL12522878 | 0.81 | PKM (1.00) | PKMSMN1; SMN2L3MBTL1ALDH1A1LMNA | |
| SCHEMBL4290225 | 0.81 | ADORA2A (0.68) | PKMSMN1; SMN2RAB9ACYP3A4CYP2C9 | |
| SCHEMBL7777979 | 0.80 | HPGD (0.64) | PKMSMN1; SMN2L3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483280-A1 | NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | Université d'Aix-Marseille (FR) | 2012-08-08 | — | — | EP | claimed |
| EP-2305688-A1 | Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors | Université de la Méditerranée - Aix-Marseille II (FR) | 2011-04-06 | — | — | EP | claimed |
| WO-2011036303-A1 | NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) | 2011-03-31 | — | — | WO | claimed |
| EP-2483280-A1 | NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | Université d'Aix-Marseille (FR) | 2012-08-08 | — | — | EP | disclosed |
| EP-2305688-A1 | Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors | Université de la Méditerranée - Aix-Marseille II (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011036303-A1 | NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) | 2011-03-31 | — | — | WO | disclosed |
| WO-2009042294-A2 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | ALPL, ALPP, ACP3 | PKM 2173/4885SMN1; SMN2 4549/4885L3MBTL1 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.